Dexcom Q3 FY25: where the revenue came from and where it went
The whole income statement of Dexcom for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Oct 30, 2025
Revenue$1.21B
+22% year over year
Gross profit$0.73B
60% margin
Operating profit$0.24B
20% margin
Net profit$0.28B
23% margin
Net profit is larger than what operations earned, because the statement adds $0.11B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.21 | 100% | +22% |
| US | 0.85 | 70% | +21% |
| Non US | 0.36 | 30% | +22% |
| Cost of revenue | −0.48 | 40% | |
| Gross profit | 0.73 | 60% margin | +1pp |
| R&D | −0.16 | 13% | −1pp |
| SG&A | −0.33 | 27% | −3pp |
| Operating profit | 0.24 | 20% margin | +5pp |
| Other income, net | 0.11 | ||
| Tax | −0.07 | ||
| Net profit | 0.28 | 23% margin | +10pp |
224 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest